Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, XS, Yan, X, Puchalski, T, Lonial, S, Lokhorst, HM, Voorhees, PM, Plesner, T, Liu, K, Khan, I, Jansson, R, Ahmadi, T, Ruixo, JJ Perez, Zhou, H, Clemens, PL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485722/
https://www.ncbi.nlm.nih.gov/pubmed/27859027
http://dx.doi.org/10.1002/cpt.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485722/
https://www.ncbi.nlm.nih.gov/pubmed/27859027
http://dx.doi.org/10.1002/cpt.577

Ejemplares similares